CRANBURY, N.J., Sept. 22, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023, before the open of the U.S. financial markets.
Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 28, 2023, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.
Schedule for the Operating Results Press Release, Conference Call / Audio Webcast
| |
Q4 & Fiscal Year End 2023 Results Press Release
| 09/28/2023 at 7:30 a.m. ET
|
Q4 & Fiscal Year End 2023 Conference Call-Live | 09/28/2023 at 11:00 a.m. ET |
US Toll Free Dial-In Number: | 1-888-506-0062 |
International Dial-In Number: | 1-973-528-0011 |
Participant Access Code:
| 313946
|
Q4 & Fiscal Year End 2023 Conference Call-Replay | 09/28/2023-10/12/2023 |
US Toll Free Dial-In Number: | 1-877-481-4010 |
International Dial-In Number: | 1-919-882-2331 |
Participant Access Code: | 49135 |
The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by accessing this link.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.
Last Trade: | US$0.12 |
Daily Volume: | 14,541 |
May 14, 2025 May 09, 2025 May 07, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load